All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

Customizing first-line BTK inhibitors for CLL

with Gilles Salles, Paolo Ghia, and Francesc Bosch

Wednesday, October 23, 2024
18:30-19:30 BST

Register now

This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-07-29T10:37:36.000Z

Reconsidering the place of BMT, BMT reporting consistency, and Q&A

Jul 29, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

During the MPN Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the place of bone marrow transplant (BMT), and BMT reporting consistency. Alessandro Vannucchi delivered a presentation on use of BMT in myelofibrosis (MF), including strategies to optimize the outcomes of BMT and considerations to be made for special populations.

Reconsidering the place of bone marrow transplant (BMT), and BMT reporting consistency

Vannucchi discusses the increase trend for the use of allogenic hematopoietic stem cell transplant (allo-HSCT) in patients as well as the age of patients with MF who may be eligible. They highlight the importance of considering the risks and benefits of transplant, consideration comorbidities, and early transplant where possible. They also highlight how to optimize transplant outcomes, discussing the role of splenomegaly and management, as well as post-transplant monitoring. This presentation concludes with a discussion on the impact of TP53 mutations and accelerated vs blast phase MF in special populations.

Q&A

Following their presentation, Vannucchi chaired a Q&A session featuring Steering Committee members Laura Michaelis, Haifa Kathrin Al-Ali, Tiziano Barbui, Steffen Koschmieder, Chloe James, and guest speaker Benjamin Rolles. Discussions include how mutations, such as ASXL1, may impact selecting BMT and ruxolitinib in the first line, and how it could be used prior to BMT to prevent GvHD.

Reconsidering the place of BMT, and BMT reporting consistency: Q&A session

Your opinion matters

As a result of this content, I commit to reviewing the latest data with luspatercept to guide my treatment of myelofibrosis-associated anemia.
21 votes - 19 days left ...

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox